Reliable diagnosis for celiac disease is currently possible only when gluten is consumed regularly. A gastroscopy and biopsy ...

The FDA has granted Fast Track designation to TEV-53408, an investigational anti-interleukin-15 antibody, for the treatment of celiac disease.

Celiac disease, traditionally considered an autoimmune disease largely localised in the gastrointestinal tract, is an ...

The findings of a new study lend support for type 1 diabetes autoantibody screening in people with other autoimmune ...

In some autoimmune disorders, autoantibodies might be present before disease onset, show remarkable specificity and serve as biomarkers providing an opportunity for diagnosis and therapeutic ...

Teva’s investigational monoclonal antibody, TEV-53408, has been designed for use in adults with celiac disease, for which a ...

The only available treatment for a patient with coeliac disease is a strict gluten-free diet, which is often not enough on ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced today that its investigational drug TEV-53408 has received Fast ...

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibodyDesignation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celia ...

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibodyDesignation underscores the potential of ...

33,623 people played the daily Crossword recently. Can you solve it faster than others?33,623 people played the daily Crossword recently. Can you solve it faster than others?

The new guidelines for the use of monoclonal antibodies (mAbs) published in Neurodegenerative Diseases, serve as exemplary clinical recommendations for clinicians and healthcare providers ...